Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T38889 |
Thailanstatin A
|
||
Thailanstatin A 是真核 RNA 剪接抑制剂,IC50为650 nM,通过非共价结合到剪接体的 U2 snRNA 亚复合物的 SF3b 亚单位发挥作用。Thailanstatin A 对多种癌细胞系的抑制显示 nM 级别的 IC50。它与 Trastuzumab 上的赖氨酸结合,可产生“无连接子” ADC。 | |||
T11917 |
Lys-SMCC-DM1
Lys-Nε-MCC-DM1 |
Microtubule Associated | Cytoskeletal Signaling |
DM1 是一种微管蛋白抑制剂。 Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) 是 DM1 的活性代谢物。 | |||
T39373 |
PNU-EDA-Gly5
PNU-EDA-Gly5 |
||
PNU-EDA-Gly5 is a DNA topoisomerase I inhibitor-based oligo-glycine linker-payload used for the synthesis of antibody-drug conjugates (ADCs). It consists of the DNA topoisomerase I inhibitor PNU-159682 and the linker EDA-Gly5. | |||
T18701 |
SPDB-DM4
|
Others | Others |
SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy. | |||
T17817 |
DBCO-(PEG)3-VC-PAB-MMAE
|
Others | Others |
DBCO-(PEG)3-VC-PAB-MMAE is a chemical compound where monomethyl auristatin E (MMAE), a potent tubulin inhibitor acting as a toxin payload in antibody-drug conjugates, is conjugated to a DBCO-(PEG)3-vc-PAB linker. | |||
T18730 |
sulfo-SPDB-DM4
|
Others | Others |
Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker. | |||
T79206 |
MC-EVCit-PAB-MMAE
|
||
MC-EVCit-PAB-MMAE (Linker-Payload 11) 作为一种ADC (drug-linker conjugates) 的代表,由具有功能性的ADC linker (MC-EVCit-PAB) 以及作为有效药物负载的微管蛋白聚合抑制剂MMAE组成。 | |||
T17799 |
DBCO-PEG4-SS-TCO
|
Others | Others |
DBCO-PEG4-SS-TCO is a cleavable 4-unit polyethylene glycol (PEG) linker essential for the synthesis of antibody-drug conjugates (ADCs)[1]. It plays a crucial role in connecting the drug payload to the antibody, enabling targeted drug delivery. | |||
T18303 |
Mal-Phe-C4-VC-PAB-MMAE
|
Others | Others |
Mal-Phe-C4-VC-PAB-MMAE is a chemical compound resulting from the conjugation of monomethyl auristatin E (MMAE), a potent tubulin inhibitor serving as a toxin payload in antibody-drug conjugates, with a Mal-Phe-C4-VC-PAB linker. | |||
T39458 |
DGN549-C
DGN549-C |
||
DGN549-C is a novel compound featuring a cleavable ADC (antibody-drug conjugate) linker composed of valine-alanine (va) and a PBD (pyrrolobenzodiazepine) dimer. This compound possesses a unique DNA-alkylating cytotoxic payload, DGN549, which is utilized in the development of ADCs. | |||
T17789 |
DBCO-(PEG2-VC-PAB-MMAE)2
|
Others | Others |
DBCO-(PEG2-VC-PAB-MMAE)2 consists of Monomethyl auristatin E (MMAE), a toxin payload in antibody-drug conjugate [1], conjugated to the cleavable linker DBCO-(PEG2-VC-PAB)2. MMAE, a potent tubulin inhibitor, serves as the cytotoxic component in this formulation. | |||
T18478 |
NAMPT inhibitor-linker 2
|
Others | Others |
NAMPT inhibitor-linker 2, a drug-linker conjugate for antibody-drug conjugates (ADCs), comprises an NAMPT inhibitor payload and a linker. When combined with an anti-c-Kit monoclonal antibody to form ADC-4, it demonstrates potent efficacy against c-Kit expressing cell lines, including GIST-T1 and NCI-H526, with IC50 values of <7 pM and 40 pM, respectively. | |||
T18477 |
NAMPT inhibitor-linker 1
|
Others | Others |
NAMPT inhibitor-linker 1, a drug-linker conjugate for ADC, integrates an NAMPT inhibitor (as a payload) with a linker. In the formulation of ADC-3, it pairs with an anti-c-Kit monoclonal antibody, demonstrating strong efficacy against c-Kit expressing cell lines, specifically GIST-T1 and NCI-H526, where it exhibits IC50 values of <3 pM and 9 pM, respectively. | |||
T15872 |
m-PEG4-Br
|
Others | Others |
m-PEG4-Br is a cleavable ADC linker used in the synthesis of antibody-drug conjugate (ADC) for Trastuzumab. m-PEG4-Br is placed distally from the monomethyl auristatin E (MMAE) payload to yield an ADC with altered hydrophilicity, antigen binding, and in v | |||
T77910 |
Patritumab deruxtecan
U3-1287,HER3-DXd |
||
Patritumab deruxtecan (HER3-DXd)为一抗体-药物偶联物(ADC),其结构为全人源IgG1单克隆抗体Patritumab通过含四肽的裂解性连接子与拓扑异构酶 I 抑制剂药效团相连。 | |||
T18522 |
PC Mal-NHS carbonate ester
|
Others | Others |
PC Mal-NHS carbonate ester is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs)[1]. This chemical compound plays a crucial role in facilitating the conjugation of drugs to antibodies, enabling targeted delivery and enhanced efficacy of therapeutic agents. Its unique carbonate ester structure allows for efficient cleavage in the targeted environment, ensuring the controlled release of the drug payload. Its application in ADC synthesis highlights its imp... | |||
T38503 |
(2-pyridyldithio)-PEG1-hydrazine
(2-pyridyldithio)-PEG1-hydrazine |
||
(2-Pyridyldithio)-PEG1-hydrazine is a one-unit cleavable polyethylene glycol (PEG) linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This linker offers the advantage of controlled release of the drug payload from the ADC construct. It is utilized in the conjugation process between the antibody and the cytotoxic drug, enabling the targeted delivery of the drug to cancer cells. The (2-pyridyldithio) group of this linker provides stability during circulation in the ... | |||
T75134 | MC-GGFG-AM-(10Me-11F-Camptothecin) | ||
MC-GGFG-AM-(10Me-11F-Camptothecin) 是ZW251合成的Linker-Payload偶联物。ZW251是靶向人GPC3的抗体-活性分子偶联物(ADC),包括人源化IgG1抗体、喜树碱(camptothecin)类的扑异构酶1抑制剂ZD06519及连接子(马来酰亚胺锚定和甘酰甘酰苯丙酰甘氨酸(GGFG)-氨基甲基(AM)可切割连接体)。该药物对人和食蟹猴GPC3具高亲和力,在表达GPC3的HCC细胞系中快速内化并可对GPC3阴性癌细胞进行旁观者介导杀伤。 | |||
T82021 |
Izeltabart
IMGC-936 |
||
Izeltabart(IMGC-936)是一款针对ADAM9的基于Maytansinoid的ADC,由与DM21-C位点特异性偶联的高亲和力人源化抗体构成,使Maytansinoid微管破坏载体通过稳定的三肽连接子进行传递,达到药物-抗体比约为2.0。Izeltabart在ADAM9阳性人类肿瘤细胞系上显示出明显的细胞毒性,并在动物异种移植肿瘤模型中展现出显著的抗肿瘤效果。 |